HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans

P. Nikamo; Björn Guðbjörnsson; L. Laasonen; L. Ejstrup; L. Iversen; U. Lindqvist; L. Padyukov; M. Ståhle

HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans

P. Nikamo^*, Björn Guðbjörnsson, L. Laasonen, L. Ejstrup, L. Iversen, U. Lindqvist, L. Padyukov, M. Ståhle

^*Corresponding author for this work

University of Iceland, Iceland, Landspitali - The National University Hospital of Iceland

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVES: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic arthritis mutilans (PAM), a severe and rare form of psoriatic arthritis (PsA).

METHODS: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without arthritis (n=1217), psoriasis without arthritis (n=534), psoriatic arthritis without mutilating disease (n=337) and psoriatic arthritis mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes.

RESULTS: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset.

CONCLUSIONS: HLA-B*27 emerges as an important genotype marker for PAM.

Original language	English
Pages (from-to)	775-780
Number of pages	6
Journal	Clinical and Experimental Rheumatology
Volume	39
Issue number	4
Publication status	Published - Jul 2021

Bibliographical note

Funding text
Funding: this work was funded by the Medical Research Council, Swedish Psoriasis Association, Welander and Finsen Foundations and Karolinska Institutet and the Nordic Psoriasis Patient Society (NORDPSO). Competing interests: none declared.

Publisher Copyright:
© Copyright CliniCal and ExpErimEntal rhEumatology 2021.

Other keywords

Arthritis
HLA-B*27
HLA-genotyping
Mutilans
Psoriasis
Genetic Predisposition to Disease
Phenotype
HLA-B Antigens/genetics
Arthritis, Psoriatic/diagnosis
Norway
Humans
Genotype

Cite this

@article{bb0e05093b36448ebef6ee1f8e6a26ce,

title = "HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans",

abstract = "OBJECTIVES: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic arthritis mutilans (PAM), a severe and rare form of psoriatic arthritis (PsA).METHODS: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without arthritis (n=1217), psoriasis without arthritis (n=534), psoriatic arthritis without mutilating disease (n=337) and psoriatic arthritis mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes.RESULTS: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset.CONCLUSIONS: HLA-B*27 emerges as an important genotype marker for PAM.",

keywords = "Arthritis, HLA-B*27, HLA-genotyping, Mutilans, Psoriasis, Genetic Predisposition to Disease, Phenotype, HLA-B Antigens/genetics, Arthritis, Psoriatic/diagnosis, Norway, Humans, Genotype",

author = "P. Nikamo and Bj{\"o}rn Gu{\dh}bj{\"o}rnsson and L. Laasonen and L. Ejstrup and L. Iversen and U. Lindqvist and L. Padyukov and M. St{\aa}hle",

note = "Funding text Funding: this work was funded by the Medical Research Council, Swedish Psoriasis Association, Welander and Finsen Foundations and Karolinska Institutet and the Nordic Psoriasis Patient Society (NORDPSO). Competing interests: none declared. Publisher Copyright: {\textcopyright} Copyright CliniCal and ExpErimEntal rhEumatology 2021.",

year = "2021",

month = jul,

language = "English",

volume = "39",

pages = "775--780",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "4",

}

TY - JOUR

T1 - HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans

AU - Nikamo, P.

AU - Guðbjörnsson, Björn

AU - Laasonen, L.

AU - Ejstrup, L.

AU - Iversen, L.

AU - Lindqvist, U.

AU - Padyukov, L.

AU - Ståhle, M.

N1 - Funding text Funding: this work was funded by the Medical Research Council, Swedish Psoriasis Association, Welander and Finsen Foundations and Karolinska Institutet and the Nordic Psoriasis Patient Society (NORDPSO). Competing interests: none declared. Publisher Copyright: © Copyright CliniCal and ExpErimEntal rhEumatology 2021.

PY - 2021/7

Y1 - 2021/7

N2 - OBJECTIVES: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic arthritis mutilans (PAM), a severe and rare form of psoriatic arthritis (PsA).METHODS: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without arthritis (n=1217), psoriasis without arthritis (n=534), psoriatic arthritis without mutilating disease (n=337) and psoriatic arthritis mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes.RESULTS: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset.CONCLUSIONS: HLA-B*27 emerges as an important genotype marker for PAM.

AB - OBJECTIVES: The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic arthritis mutilans (PAM), a severe and rare form of psoriatic arthritis (PsA).METHODS: Cohorts of patients with the diagnosis of psoriasis vulgaris with or without arthritis (n=1217), psoriasis without arthritis (n=534), psoriatic arthritis without mutilating disease (n=337) and psoriatic arthritis mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes.RESULTS: The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset.CONCLUSIONS: HLA-B*27 emerges as an important genotype marker for PAM.

KW - Arthritis

KW - HLA-B27

KW - HLA-genotyping

KW - Mutilans

KW - Psoriasis

KW - Genetic Predisposition to Disease

KW - Phenotype

KW - HLA-B Antigens/genetics

KW - Arthritis, Psoriatic/diagnosis

KW - Norway

KW - Humans

KW - Genotype

UR - http://www.scopus.com/inward/record.url?scp=85109725338&partnerID=8YFLogxK

UR - https://www.clinexprheumatol.org/abstract.asp?a=15653

M3 - Article

C2 - 32896263

AN - SCOPUS:85109725338

SN - 0392-856X

VL - 39

SP - 775

EP - 780

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 4

ER -

HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans

Abstract

Bibliographical note

Other keywords

Fingerprint

Cite this